Mizuho sets USD 22.00 target for REGENXBIO stock

Published on 10/15/2026 at 20:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

REGENXBIO schedules an October 20, 2026 wet AMD event. REGENXBIO stock costs EUR 6.27 on October 15, 2026 beside USD 7.02 on Nasdaq.

Analyst view and company calendar

On October 5, 2026, Mizuho set a USD 22.00 price target for REGENXBIO.
REGENXBIO scheduled a wet age-related macular degeneration event for October 20, 2026.
REGENXBIO stock costs EUR 6.27 at Lang & Schwarz on October 15, 2026 at 8:07 p.m. CEST.
REGENXBIO had a USD 463.5 million market capitalization as of October 15, 2026.

RGNX, US75901B1070, Illustration mit AI erstellt.

Mizuho set a USD 22.00 price target for REGENXBIO on October 5, 2026, according to Investing.com. Against the USD 7.02 Nasdaq price at 2:12 p.m. ET on October 15, 2026, that target stands 213.68 percent higher. REGENXBIO was trading at EUR 6.27 at Lang & Schwarz on October 15, 2026 at 8:07 p.m. CEST.

October event sets the next date

REGENXBIO's investor calendar lists a wet age-related macular degeneration program overview and expert perspectives for October 20, 2026, at 1:00 p.m. EDT. The event concerns sura-vec, the company's name for ABBV-RGX-314, which it is developing with AbbVie. The date and program description appear on the company's investor-relations page at REGENXBIO.

Stock sits above its yearly low

The Nasdaq price of USD 7.02 was 28.57 percent above the 52-week low of USD 5.46 and 56.64 percent below the 52-week high of USD 16.19 on October 15, 2026. Trading volume reached 489,178 shares against an average of 1,488,034 shares. The session range ran from USD 6.83 to USD 7.07.

Valuation and company scale

REGENXBIO had a market capitalization of USD 463.5 million on October 15, 2026. In the second quarter of 2026, revenue came to USD 108.02 million, while net income attributable to common shareholders was USD 22.71 million. MarketBeat reported second-quarter earnings per share of USD 0.43 against a consensus estimate of USD 0.08 on October 15, 2026.

Comparison with peers

REGENXBIO (Nasdaq, USD): plus 2.05 percent, market capitalization USD 463.5 million
Sarepta Therapeutics (Nasdaq, USD): plus 4.55 percent, market capitalization USD 1.9 billion
Rocket Pharmaceuticals (Nasdaq, USD): plus 4.52 percent, market capitalization USD 253.6 million

Price and investor perspective

The market picture combines a clinical-stage biotechnology valuation with a scheduled program update. The October 20 event gives investors a dated point for assessing the wet AMD program and its development path.

REGENXBIO was trading at EUR 6.27 at Lang & Schwarz on October 15, 2026 at 8:07 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of REGENXBIO stock.